Coronary Heart Disease News and Research

RSS

SPI-Bio to distribute and sell Aterovax's sPLA2 activity test in Europe

Aterovax SA, a company developing innovative products for atherosclerosis, today announced the signing of a 3 year, exclusive agreement with SPI-Bio, a specialist distributor of products and services in drug development, to distribute and sell Aterovax's sPLA2 activity test in Europe to academic and research laboratories for research use.

19 Apr 2010

New study may help devise better treatment strategies for cancer and heart disease

Research led by T. Cooper Woods, PhD, Assistant Professor of Pharmacology and Experimental Therapeutics at LSU Health Sciences Center New Orleans, and Director of the Molecular Cardiology Research Laboratory at Ochsner Clinic Foundation, has identified the mechanism of how a drug commonly used on stents to prevent reclosure of coronary arteries, regulates cell movement which is critical to wound healing and the progression of diseases like cancer.

16 Apr 2010

XOMA expands anti-inflammatory antibody intellectual property portfolio

XOMA Ltd., a leader in the discovery and development of therapeutic antibodies, announced that the U.S. Patent and Trademark Office has issued two new patents that significantly expand the company's intellectual property portfolio relating to its anti-inflammatory antibody, XOMA 052, that targets interleukin-1 beta (IL-1 beta).

13 Apr 2010

High glycemic diet in women linked to increased risk of coronary heart disease

Consuming carbohydrates with high glycemic index—an indicator of how quickly a food affects blood glucose levels—appears to be associated with the risk of coronary heart disease in women but not men, according to a report in the April 12 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.

13 Apr 2010

Genes influence chronic kidney disease risk: Research

A team of researchers from the United States and Europe has identified more than a dozen genes that may play a role in the etiology of common forms of kidney disease. The team, known as the CKDGen Consortium, examined common variations in DNA sequences in more than 65,000 individuals of European descent. Common variations in several genes were found to be more frequent among people with poor kidney function or chronic kidney disease than in those with normal kidney function.

13 Apr 2010

Researchers evaluate new treatment for coronary heart disease

Some patients with heart muscles seriously affected by coronary heart disease may soon be able to benefit from an innovative treatment.

13 Apr 2010

Results of research study on the expression of KIF6 in mouse model

Celera Corporation and its collaborators at The University of Washington, WA, and Indiana University, IN, today announced the presentation of data from a research study that investigated the expression of KIF6 in a mouse Celera Corporation model. A key finding was that KIF6 was specifically expressed in macrophages and chondrocytes in mouse atherosclerotic lesions, but not in normal arteries.

12 Apr 2010

Ultrasound scan of carotid artery improves prediction of heart disease: Research

New research shows that doing a simple ultrasound scan of the carotid artery significantly improves the prediction of heart disease, giving doctors a better clue of who is at high risk for a heart attack.

8 Apr 2010

Comprehensive cardiac health study provides superior results

Kenneth "Buddy" Conant hit some clothing stores for a little shopping spree recently, but it wasn't because he'd suddenly become enthralled with the latest fashions. The truth was, he was starting to resemble a kid wearing a grown man's clothes.

6 Apr 2010

Young adults with hyperthyroidism face increase risk of stroke

Young adults with overactive thyroid face a 44 percent increased risk of stroke compared to those with normal thyroid function, according to a study reported in Stroke: Journal of the American Heart Association.

3 Apr 2010

Naturalhealthylife.co.uk celebrates National Garlic Day

Naturalhealthylife.co.uk, the official UK site for herbal supplements made by Klosterfrau, are celebrating National Garlic Day on Monday 19th April. Klosterfrau is a leading manufacturer of herbal healthcare products.

29 Mar 2010

Ford Motor donates $255,000 to fund completion of Oakwood Healthcare System's research study

Ford Motor Company announced today it is donating an additional $255,000 to fund the completion of a pioneering multi-year Oakwood Healthcare System research study into the prevention of heart disease – a leading cause of death among American women.

27 Mar 2010

Pravastatin benefits elderly carriers of KIF6 gene variant with prior vascular disease

Celera Corporation today announced the publication of data reporting that elderly (over age 70) carriers of the KIF6 gene variant with prior vascular disease received significant benefit from pravastatin (Pravachol®) therapy. Previous research has shown that a variant of the KIF6 gene, a member of the molecular motor protein kinesin family, is associated with up to a 55% increased risk of primary and recurrent coronary heart disease (CHD) events in the placebo arms of the clinical trials, and that this increased risk is virtually eliminated with statin therapy.

26 Mar 2010

Interim results from ZALBIN Phase 2B trial in chronic hepatitis C patients announced

Human Genome Sciences, Inc. today announced interim results through Week 12 following the end of treatment in a Phase 2b clinical trial conducted by Novartis to evaluate the safety and efficacy of ZALBIN™ (albinterferon alfa-2b), an investigational agent, administered monthly in combination with ribavirin in 391 treatment-naive patients with genotypes 2 and 3 chronic hepatitis C virus. The primary efficacy endpoint is sustained virologic response (SVR) at Week 48 (24 weeks following the end of treatment).

26 Mar 2010

Study: Replacing dietary saturated fats with polyunsaturated fatty acids reduces coronary heart disease

A study in this week's PLoS Medicine shows that the replacement of dietary saturated fatty acids with polyunsaturated fatty acids reduces coronary heart disease events, bringing much needed scientific evidence to an issue debated by experts and clinical guidelines.

23 Mar 2010

AstraZeneca's CRESTOR: Health Canada approves new indication

AstraZeneca announced today that Health Canada has approved CRESTOR (rosuvastatin calcium) to reduce the risk of nonfatal myocardial infarction (heart attack), nonfatal stroke, and coronary artery revascularization in adult patients without documented history of cardiovascular or cerebrovascular events, but with at least two conventional risk factors for cardiovascular disease.

17 Mar 2010

Human Genome Sciences announces Phase 2 results of mapatumumab combination therapy for NSCLC

Human Genome Sciences, Inc. today announced the results of its randomized Phase 2 trial of mapatumumab (HGS-ETR1) in combination with the chemotherapy agents paclitaxel and carboplatin as first-line therapy in advanced non-small cell lung cancer (NSCLC).

17 Mar 2010

Lipitor 80 mg may help reduce risk of major cardiovascular events in high-risk patients

Lipitor® (atorvastatin calcium) 80 mg was associated with a significantly reduced risk of major cardiovascular events compared with Lipitor 10 mg among patients with both coronary heart disease (CHD) and chronic kidney disease (CKD) who were obese or had metabolic syndrome. These data, from two sub-analyses of the Treating to New Targets (TNT) trial that were designed and completed following the completion of TNT, were presented today at the 59th Annual Scientific Session of the American College of Cardiology (ACC) in Atlanta, Ga.

16 Mar 2010

Tips for reducing LDL cholesterol

Cardiovascular disease is the No.1 killer in North America. And high cholesterol is one of the primary risk factors of coronary heart disease and stroke. According to the Heart and Stroke Foundation, almost 40% of Canadian adults are classified as having high blood cholesterol levels.

16 Mar 2010

Genzyme, Isis Pharmaceuticals: Phase 3 study of mipomersen in hoFH patients meets primary endpoint

Genzyme Corp. and Isis Pharmaceuticals Inc. today announced that data from a phase 3 study of mipomersen in patients with homozygous familial hypercholesterolemia (hoFH) were published in The Lancet. This study met its primary endpoint, resulting in an average LDL-C reduction of greater than 100 mg/dL in this very high-risk patient population.

16 Mar 2010

Coronary Heart Disease News and Research

SPI-Bio to distribute and sell Aterovax's sPLA2 activity test in Europe

New study may help devise better treatment strategies for cancer and heart disease

XOMA expands anti-inflammatory antibody intellectual property portfolio

High glycemic diet in women linked to increased risk of coronary heart disease

Genes influence chronic kidney disease risk: Research

Researchers evaluate new treatment for coronary heart disease

Results of research study on the expression of KIF6 in mouse model

Ultrasound scan of carotid artery improves prediction of heart disease: Research

Comprehensive cardiac health study provides superior results

Young adults with hyperthyroidism face increase risk of stroke

Naturalhealthylife.co.uk celebrates National Garlic Day

Ford Motor donates $255,000 to fund completion of Oakwood Healthcare System's research study

Pravastatin benefits elderly carriers of KIF6 gene variant with prior vascular disease

Interim results from ZALBIN Phase 2B trial in chronic hepatitis C patients announced

Study: Replacing dietary saturated fats with polyunsaturated fatty acids reduces coronary heart disease

AstraZeneca's CRESTOR: Health Canada approves new indication

Human Genome Sciences announces Phase 2 results of mapatumumab combination therapy for NSCLC

Lipitor 80 mg may help reduce risk of major cardiovascular events in high-risk patients

Tips for reducing LDL cholesterol

Genzyme, Isis Pharmaceuticals: Phase 3 study of mipomersen in hoFH patients meets primary endpoint

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News